APA (7th ed.) Citation

A, J., A, R., TJ, W., C, H., P, H., B, H., . . . B, K. (2022). Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers. Annals of oncology : official journal of the European Society for Medical Oncology, 33(11), 1186. https://doi.org/10.1016/j.annonc.2022.07.008

Chicago Style (17th ed.) Citation

A, Jahn, et al. "Comprehensive Cancer Predisposition Testing Within the Prospective MASTER Trial Identifies Hereditary Cancer Patients and Supports Treatment Decisions for Rare Cancers." Annals of Oncology : Official Journal of the European Society for Medical Oncology 33, no. 11 (2022): 1186. https://doi.org/10.1016/j.annonc.2022.07.008.

MLA (9th ed.) Citation

A, Jahn, et al. "Comprehensive Cancer Predisposition Testing Within the Prospective MASTER Trial Identifies Hereditary Cancer Patients and Supports Treatment Decisions for Rare Cancers." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 33, no. 11, 2022, p. 1186, https://doi.org/10.1016/j.annonc.2022.07.008.